Abstract:
Despite recent advances in multimodality therapy for glioblastoma (GB) incorporating
surgery, radiotherapy, chemotherapy and targeted therapy, the overall prognosis remains poor. One
of the interesting targets for GB therapy is the histone deacetylase family (HDAC). Due to their
pleiotropic effects on, e.g., DNA repair, cell proliferation, differentiation, apoptosis and cell cycle,
HDAC inhibitors have gained a lot of attention in the last decade as anti-cancer agents. Despite
their known underlying mechanism, their therapeutic activity is not well-defined. In this review, an
extensive overview is given of the current status of HDAC inhibitors for GB therapy, followed by an
overview of current HDAC-targeting radiopharmaceuticals. Imaging HDAC expression or activity
could provide key insights regarding the role of HDAC enzymes in gliomagenesis, thus identifying
patients likely to benefit from HDACi-targeted therapy.
